Table 3. Studies reviewed for incidence and ROM of nuclear vs. architectural atypia in AUS/FLUS.
| Study | Country | Study period | No. of AUS/FLUS | AUS-A | AUS-N | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. of cases | R | M | I | ROM | No. of cases | R | M | I | ROM | |||||
| Asian | ||||||||||||||
| Gan 2017, (16) | Singapore | 2008–2014 | 309 | NA | 75 | 11 | NA | 0.147 | NA | 57 | 21 | NA | 0.368 | |
| Chung 2011, (25) | Korea | 2005–2010 | 515 | NA | 4 | 2 | NA | 0.500 | NA | 92 | 55 | NA | 0.598 | |
| Ryu 2014, (98) | Korea | 2008–2012 | NR | NA | 61 | 15 | NA | 0.246 | NA | 55 | 26 | NA | 0.473 | |
| Hyeon 2014, (26) | Korea | 2011–2012 | 551 | 120 | 38 | 5 | 0.218 | 0.132 | 431 | 193 | 152 | 0.782 | 0.788 | |
| Park 2014, (7) | Korea | 2010–2011 | 331 | 42 | 9 | 2 | 0.127 | 0.222 | 214 | 68 | 66 | 0.647 | 0.971 | |
| Dincer 2013, (15) | Turkey | 2009–2010 | 368 | 85 | 26 | 7 | 0.231 | 0.269 | 283 | 62 | 16 | 0.769 | 0.258 | |
| Çuhaci 2014, (14) | Turkey | 2010–2012 | NR | NA | 91 | 18 | NA | 0.198 | NA | 185 | 45 | NA | 0.243 | |
| Onder 2014, (13) | Turkey | 2009–2012 | 421 | 134 | 34 | 2 | 0.318 | 0.059 | 257 | 62 | 16 | 0.610 | 0.258 | |
| Non-Asian | ||||||||||||||
| Luu 2011, (8) | USA | 2004–2009 | 222 | 154 | 79 | 11 | 0.694 | 0.139 | 68 | 48 | 22 | 0.306 | 0.458 | |
| Olson 2011, (61) | USA | 2009–2011 | 388 | NA | 30 | 8 | NA | 0.267 | NA | 62 | 30 | NA | 0.484 | |
| VanderLaan 2011, (6) | USA | 2005–2009 | 512 | NA | 45 | 11 | NA | 0.244 | NA | 84 | 40 | NA | 0.476 | |
| Horne 2012, (64) | USA | 2008–2009 | 171 | 107 | 25 | 4 | 0.626 | 0.160 | 64 | 33 | 25 | 0.374 | 0.758 | |
| Ho 2014, (70) | USA | 2008–2011 | 709 | NA | 78 | 44 | NA | 0.564 | NA | 28 | 15 | NA | 0.536 | |
| Lee 2014, (71) | USA | 2011–2012 | 122 | NA | 41 | 10 | NA | 0.244 | NA | 16 | 4 | NA | 0.250 | |
| Mathur 2014, (72) | USA | 2009–2013 | 806 | NA | 49 | 19 | NA | 0.388 | NA | 105 | 57 | NA | 0.543 | |
| Walts 2014, (75) | USA | 2008–2012 | 457 | NA | 52 | 7 | NA | 0.135 | NA | 75 | 36 | NA | 0.480 | |
| Wu 2014, (12) | USA | 2002–2008 | 670 | NA | 32 | 8 | NA | 0.250 | NA | 41 | 13 | NA | 0.317 | |
| Shrestha 2016, (80) | USA | 2006–2012 | 221 | NA | 21 | 2 | NA | 0.095 | NA | 66 | 23 | NA | 0.348 | |
| Valderrabano 2017, (5) | USA | 2008–2015 | 241 | 105 | 62 | 2 | 0.436 | 0.030 | 84 | 42 | 17 | 0.349 | 0.400 | |
| Bernstein 2016, (87) | Canada | 2010–2013 | 233 | 122 | 84 | 34 | 0.524 | 0.405 | 111 | 103 | 52 | 0.476 | 0.505 | |
| Srbova 2015, (99) | Czech | 2001–2012 | NR | NA | 33 | 3 | NA | 0.091 | NA | 43 | 10 | NA | 0.233 | |
| Rossi 2017, (100) | Italy | 2008–2009 | 269 | 140 | 102 | 27 | 0.520 | 0.265 | 46 | 40 | 26 | 0.171 | 0.650 | |
| Fatman 2015, (97) | S. Africa | 2008–2011 | 141 | 93 | 20 | 8 | 0.660 | 0.400 | 48 | 24 | 9 | 0.340 | 0.375 | |
AUS/FLUS, atypia of undetermined significance/follicular lesion of undetermined significance; AUS-A, AUS/FLUS with architectural atypia; AUS-N, AUS/FLUS with nuclear atypia; R, number of resected cases; M, number of malignant cases; I, incidence; ROM, risk of malignancy; NA, not available.